Evonik reported a solid start to the new year despite the economic slowdown caused by the corona pandemic. In particular, the two growth segments Resource Efficiency and Nutrition & Care held their course in a challenging environment. The company’s sales decreased slightly by 1% to €3.24 billion in the first quarter compared with the previous year. Adjusted earnings before interest, tax, depreciation and amortization (EBITDA) fell 5% to €513 million. “We implemented measures early and...